Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly began marketing its rival product Mounjaro in the world's most populous nation.

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough offers hope for safer obesity treatments but raises caution over possible side effects.

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.